MURA (Mural Oncology) Pre-Tax Income : $-151.80 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Mural Oncology's pretax income for the three months ended in Sep. 2024 was $-31.76 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-151.80 Mil. Mural Oncology's pretax margin was %.

Mural Oncology Pre-Tax Income Historical Data

The historical data trend for Mural Oncology's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Pre-Tax Income Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Pre-Tax Income

-175.37

-184.92

-195.29

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial						-46.31	-57.56	-30.92	-31.56	-31.76

Competitive Comparison of Mural Oncology's Pre-Tax Income

For the Biotechnology subindustry, Mural Oncology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mural Oncology's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Pre-Tax Income falls into.

Mural Oncology Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Mural Oncology's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-196.238	+	0.951	+	0	+	0	+	0
	=	-195.29

Mural Oncology's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-34.098	+	2.339	+	0	+	0	+	0
	=	-31.76

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-151.80 Mil.

Mural Oncology (NAS:MURA) Pre-Tax Income Explanation

Mural Oncology's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-31.759	/	0
	=	%

Mural Oncology Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.